Researchers have found two specific genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers that could help doctors detect idiopathic pulmonary arterial hypertension (IPAH) earlier and possibly guide treatment.
This study, published in Scientific Reports on July 12, 2025, focused on genes linked to ferroptosis, an iron-dependent type of cell death connected to lung diseases and previously linked to idiopathic pulmonary arterial hypertension.
The researchers also identified an existing drug, ustekinumab, a protein inhibitor, involved in and used to treat the regulation of the immune system and inflammation, that might be repurposed to treat idiopathic pulmonary arterial hypertension in the future.
Summary by Suzanne Lea, Alliance for Pulmonary Hypertension volunteer
Read more at this link on Pulmonary Hypertension News